当前位置:
X-MOL 学术
›
Eur. J. Neurol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study
European Journal of Neurology ( IF 5.1 ) Pub Date : 2021-08-23 , DOI: 10.1111/ene.15075 Simone de Vries Lentsch 1 , Iris E Verhagen 1, 2 , Thomas C van den Hoek 1 , Antoinette MaassenVanDenBrink 2 , Gisela M Terwindt 1
European Journal of Neurology ( IF 5.1 ) Pub Date : 2021-08-23 , DOI: 10.1111/ene.15075 Simone de Vries Lentsch 1 , Iris E Verhagen 1, 2 , Thomas C van den Hoek 1 , Antoinette MaassenVanDenBrink 2 , Gisela M Terwindt 1
Affiliation
New prophylactics for migraine, targeting calcitonin gene-related peptide (CGRP), have recently emerged. Real-world data are important for a comprehensive understanding of treatment response. We assessed the consistency of response to erenumab, a monoclonal CGRP receptor antibody, in a real-world setting, in order to determine which patients may be considered responders in clinical practice.
中文翻译:
用单克隆降钙素基因相关肽受体抗体erenumab治疗:一项真实的研究
最近出现了针对降钙素基因相关肽 (CGRP) 的新型偏头痛预防药。真实世界的数据对于全面了解治疗反应非常重要。我们在真实环境中评估了对 erenumab(一种单克隆 CGRP 受体抗体)反应的一致性,以确定哪些患者在临床实践中可能被视为反应者。
更新日期:2021-08-23
中文翻译:
用单克隆降钙素基因相关肽受体抗体erenumab治疗:一项真实的研究
最近出现了针对降钙素基因相关肽 (CGRP) 的新型偏头痛预防药。真实世界的数据对于全面了解治疗反应非常重要。我们在真实环境中评估了对 erenumab(一种单克隆 CGRP 受体抗体)反应的一致性,以确定哪些患者在临床实践中可能被视为反应者。